The US Food and Drug Administration has approved a diabetes drug as a treatment for obesity. It’s the first injectable drug approved for weight loss.

The drug, liraglutide, will be marketed under the brand name Saxenda by its maker, Novo Nordisk.

• Most radioactive place on earth in Australia?
• ‘Magic’ arthritis treatment gives hope to sufferers
• Children and tragedy: how to help kids cope

It is approved for obese adults and for overweight adults who have at least one weight-related health problem like type 2 diabetes, high blood pressure, or high cholesterol.

The FDA approved liraglutide in 2010 as a treatment for type 2 diabetes, and Novo Nordisk sells it under the name Victoza as a treatment for that condition. Saxenda contains a larger dose of liraglutide than Victoza does.

Liraglutide is part of a new group of medicines, called GLP-1 agonists, that are designed to spur the pancreas to create extra insulin after meals.

The FDA has approved three weight loss pills in recent years. It cleared Vivus Inc’s Qsymia and Arena Pharmaceuticals’s Belviq in 2012 and granted approval to Orexigen Therapeutics’s drug Contrave in September.